Ref (type)	Population	Outcome, Interventions	Results and statistical analysis	Effect size	Favours
Adverse effects
RCT Crossover design 3-armed trial	22 people In review	Adverse effects (not further detailed) 10/22 (45%) with nifedipine 10 mg 16/22 (72%) with nifedipine 20 mg 6/22 (27%) with placebo	Significance not assessed
RCT Crossover design	26 people In review	Adverse effect 16/21 (76%) with nifedipine Not reported with placebo
RCT	Number of people not reported In review	Oedema 24% with nifedipine 0% with placebo	P = 0.01	Effect size not calculated	placebo
RCT	Number of people not reported In review	Flushing 8% with nifedipine 0% with placebo	P = 0.01	Effect size not calculated	placebo
RCT	Total number of people not reported In review	Tachycardia 2 people with nifedipine 0 people with placebo	Significance not assessed
RCT	39 people In review	Overall adverse effects with nifedipine with placebo Absolute results not reported	Reported as not significant P value not reported		Not significant
RCT	39 people In review	Palpitations 7/18 (39%) with nifedipine 1/18 (6%) with placebo	P <0.05	Effect size not calculated	placebo
RCT Crossover design	23 people In review	Adverse effects (post-crossover results) 14/23 (61%) with nifedipine 2/23 (9%) with placebo	P = 0.05	Effect size not calculated	placebo
RCT Crossover design	34 people In review	Adverse effects (post-crossover results) 12 weeks 26/34 (76%) with nifedipine 5/34 (15%) with placebo	Significance not assessed